Bristol-Myers Squibb Company $(BMY)$ has priced a public offering of senior unsecured notes with a combined aggregate principal amount of €5 billion, to be issued by its wholly-owned subsidiary, BMS Ireland Capital Funding Designated Activity Company. The offering comprises five tranches: - €750,000,000 of 2.973% Notes due 2030 - €1,150,000,000 of 3.363% Notes due 2033 - €1,150,000,000 of 3.857% Notes due 2038 - €750,000,000 of 4.289% Notes due 2045 - €1,200,000,000 of 4.581% Notes due 2055 The Notes will be fully and unconditionally guaranteed on a senior unsecured basis by Bristol-Myers Squibb Company. Closing of the offering is expected on November 10, 2025, subject to customary conditions. The company plans to use the net proceeds, along with approximately $3.0 billion in cash on hand, primarily to fund a concurrent tender offer and for general corporate purposes. The full prospectus is available at https://www.sec.gov.